Multivariate Analysis in the Pharmaceutical Industry (e-bog) af -
Tobyn, Mike (redaktør)

Multivariate Analysis in the Pharmaceutical Industry e-bog

1240,73 DKK (inkl. moms 1550,91 DKK)
Multivariate Analysis in the Pharmaceutical Industry provides industry practitioners with guidance on multivariate data methods and their applications over the lifecycle of a pharmaceutical product, from process development, to routine manufacturing, focusing on the challenges specific to each step. It includes an overview of regulatory guidance specific to the use of these methods, along with ...
E-bog 1240,73 DKK
Forfattere Tobyn, Mike (redaktør)
Udgivet 24 april 2018
Længde 464 sider
Genrer Quality Assurance (QA) and Total Quality Management (TQM)
Sprog English
Format pdf
Beskyttelse LCP
ISBN 9780128110669
Multivariate Analysis in the Pharmaceutical Industry provides industry practitioners with guidance on multivariate data methods and their applications over the lifecycle of a pharmaceutical product, from process development, to routine manufacturing, focusing on the challenges specific to each step. It includes an overview of regulatory guidance specific to the use of these methods, along with perspectives on the applications of these methods that allow for testing, monitoring and controlling products and processes. The book seeks to put multivariate analysis into a pharmaceutical context for the benefit of pharmaceutical practitioners, potential practitioners, managers and regulators. Users will find a resources that addresses an unmet need on how pharmaceutical industry professionals can extract value from data that is routinely collected on products and processes, especially as these techniques become more widely used, and ultimately, expected by regulators. Targets pharmaceutical industry practitioners and regulatory staff by addressing industry specific challenges Includes case studies from different pharmaceutical companies and across product lifecycle of to introduce readers to the breadth of applications Contains information on the current regulatory framework which will shape how multivariate analysis (MVA) is used in years to come